Participation of Ras and extracellular regulated kinase in the hyperplastic response of middle-ear mucosa during bacterial otitis media

Journal of Infectious Diseases

Volumn 186, Issue 12, 2002, Pages 1761-1769

  Palacios, Sean D ^a   Pak, Kwang ^a   Kayali, Ayse G ^b   Rivkin, Alexander Z ^a   Aletsee, Christoph ^c   Melhus, Åsa ^d   Webster, Nicholas J G ^b   Ryan, Allen F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; CELL HYPERPLASIA; CELL PROLIFERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ANALYSIS; GROWTH REGULATION; GROWTH STIMULATION; INTRACELLULAR TRANSPORT; MALE; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; RAT;

ANIMALS; BUTADIENES; DISEASE MODELS, ANIMAL; EAR, MIDDLE; ENZYME INHIBITORS; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HYPERPLASIA; MALE; METHIONINE; MITOGEN-ACTIVATED PROTEIN KINASES; MUCOUS MEMBRANE; NITRILES; OTITIS MEDIA; RAS PROTEINS; RATS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 0037114939     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345798     Document Type: Article

References (60)

1. Junqueira LC, Carneiro J, Kelley RO. Basic Histology. Norwalk, CT: Appleton & Lange. 1995.
2. Koutnouyan HA, Baird A, Ryan AF. Acidic and basic FGF mRNA expression in the middle ear mucosa during experimental acute and chronic otitis media. Laryngoscope 1994;104:350-8.
3. Ryan AF. A Baird. Growth factors during proliferation of the middle ear mucosa. Acta Otolaryngol 1993;113:68-74.
4. Lim D, Birck H. Ultrastructural pathology of the middle ear mucosa in serous otitis media. Ann Otol Rhinol Laryngol 1971;80:838-53.
5. Keithley EM, Krekorian T, Sharp P, Harris JP, Ryan AF. Comparison of immune-mediated models of acute and chronic otitis media. Arch Otorhinolaryngol 1990;247:247-51.
6. Kuijpers W. van der Beck JMH. Willart ECT The effect of experimental tubal obstruction on the middle ear. Acta Otolaryngol 1979;87:345-52.
7. Lowell S, Juhn SK, Giebink GS. Experimental otitis media following middle ear inoculation of nonviable streptococcus pneumoniae. Ann Otol Rhinol Laryngol 1980;89:479-82.
8. Magnuson K, Hermansson A, Melhus A, Hellstrom S. The tympanic membrane and middle ear mucosa during non-typeable Haemophilus influenzae and Haemophilus influenzae type b acute otitis media: A study in the rat. Acta Otolaryngol 1997;117:396-405.
9. Krekorian T, Keithley EM, Takahashi M, Ryan AF, Fierir J, Harris JP. Endotoxin induced otitis media with effusion in the mouse. Acta Otolaryngol 1990;109:288-99.
10. DeMaria TF, Billy JM, Danahey DG. Growth factors during endotoxin-induced experimental otitis media. Acta Otolaryngol 1996;116:854-6.
11. Ryan AF, Catanzaro A, Wasserman S. Harris JP. Secondary immune response in the middle ear: Physiological, anatomical and immunological observations. Ann Otol Rhinol Laryngol 1986;95:242-9.
12. Catanzaro A, Ryan AF, Butcher S. The response to human rIL-1, rIL-2 and rTNF in the middle ear of guinea pigs. Laryngoscope 1991;101:271.
13. Mawson S, Fagan P. Tympanic effusions in children: Long-term results of treatment by myringotomy, aspiration, and indwelling tubes. J Laryngol Otol 1972;86:105-19.
14. Morgan W Jr. Tympanosclerosis. Laryngoscope 1977;87:1821-5.
15. Kilby D, Richards S, Hart G. Grommets and glue ears: Two-year results. J Laryngol Otol 1972;86:881-8.
16. Sade J. Pathogenesis of attic cholesteatoma: the metaplasia theory. In: McCabe BF, Sade J, Abramson M, eds. Cholesteatoma: First International Conference. Birmingham, AL: Aesculapius, 1978;212-32.
17. Cawthorne T. Chronic adhesive otitis. J Laryngol Otol 1956;70:559-64.
18. Sheehy J, Brackmann D, Graham M. Cholesteatoma surgery: residual and recurrent disease - a review of 1,024 cases. Ann Otol Rhinol Laryngol 1977;86:451-62.
19. Palacios SD, Oehl HJ, Rivkin AZ, Aletsee C, Pak K, Ryan AF. Growth factors influence growth and differentiation of the middle ear mucosa. Laryngoscope 2001;110:874-80.
20. Baird A, Walicke PA. Fibroblast growth factors. Br Med Bull 1989;45:438-52.
21. Gospodarowicz D. Fibroblast growth factor - Chemical structure and biological function. Clin Orthop 1990;257:231-48.
22. Van Blitterswijk C, Ponec M. Van Muijen G, Wijsman M, Koerten H, Grote J. Culture and characterization of rat middle-ear epithelium. Acta Otolaryngol 1986;101:453-66.
23. Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 1994;19:459-63.
24. Olson M, Marais R. Ras protein signaling. Semin Immunol 2000;12:63-73.
25. Berhard E, McKenna W, Hamilton A, et al. Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 1998;58:1754-61.
26. Leonard D. Ras farnesyltransferase: A new therapeutic target. J Med Chem 1997;40:19.
27. Egan S, Weinberg R. The pathways to signal achievement. Nature 1993;365, 781-6.
28. Vojtek A, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998;273:19925-8.
29. Kato K, Der CJ, Buss J. Prenoids and palmitate: Lipids that control the biological activity of Ras proteins. Semin Cancer Biol 1992;3:179-88.
30. Casey P. Protein prenyltransferases. J Biol Chem 1996;271:5289-92.
31. Lerner E, Qian Y, Blaskovich M, et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 1995;270:26802-6.
32. Huang C, Chen C, Huang T, Shinoda H. Mediation of signal tranasduction in keratinocytes of human middle ear cholesteatoma by ras protein. Eur Arch Otorhinolaryngol 1996;253:385-9.
33. Jones M. Tomikawa M, Mohajer B, Tarnawski A. Gastrointestinal mucosal regeneration: Role of growth factors. Front Biosci 1999;4:D303-9.
34. Melhus A, Hermansson A, Akkoyunlu M, Forsgren A, Prellner K. Experimental recurrent otitis media induced by Haemophilus influenzae: Protection and serum antibodies. Am J Otolaryngol 1995;16:383-90.
35. Melhus A, Hermansson A, Prellner K. Nontypeable and encapsulated Haemophilus influenzae yield different clinical courses of experimental otitis media. Acta Otolaryngol 1994;114:289-94.
36. Friedmann I. The comparative pathology of otitis media - Experimental and human. II. The histopathology of experimental otitis of the guinea pig with particular reference to experimental cholesteatoma. J Laryngol 1955;69: 588-601.
37. Campbell S, Khosravi-Far R, Rossman K. Clark G. Der C. Increasing complexity of Ras signaling. Oncogene 1998;17:1395-413.
38. Ewen M. Relationship between ras pathways and cell cycle control. Prog Cell Cycle Res 2000;4:1-17.
39. Du W, Lebowitz P, Prendergast G. Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho. Oncogene 1998;17:1439-45.
40. Goldsworthy T, Goldsworthy S, Sprankle C, Butterworth B. Expression of myc, fos and Ha-ras associated with chemically induced cell proliferation in the rat liver. Cell Prolif 1994;27:269-78.
41. Prevost G, Pradines A, Viossat I, et al. Inhibition of human tumor cell growth in vitro and in vivo by a specific inhibitor of human farnesyltransferase: BIM-46068. Int J Cancer 1999;83:283-7.
42. Barbacid M. Ras genes. Annu Rev Biochem 1987;56:779-827.
43. Lerner E, Zhang T, Knowles D, Qian Y, Hamilton A, Sevti S. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 1997;15:1283-8.
44. Dieckgraefe B, Weems D, Santoro S, Alpers D. ERK and p38 MAP kinase pathways are mediators of intestinal epithelial wound-induced signal transduction. Biochem Biophys Res Commun 1997;233:389-94.
45. Senmaru N, Shichinohe T, Takeuchi M, et al. Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y. Int J Cancer 1998;78:366-71.
46. Qui M, Green S. PC12 cell neuronal differentiation is associated with prolonged p21ras activity and consequent prolonged ERK activity. Neuron 1992;9:705-17.
47. Plattner R, Gupta S, Khosravi-Far R, et al. Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. Oncogene 1999;18:1807-17.
48. Yip-Schneider M, Lin A, Barnard D, Sweeney C, Marshall M. Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression. Int J Oncol 1999;15:271-9.
49. + channels. Cell 1990;61:769-76.
50. Feig L, Urano T, Cantor S. Evidence for a Ras/Ral signaling cascade. Trends Biochem Sci 1996;21:438-41.
51. Van Aelst L, White M, Wigler M. Ras partners. Cold Spring Harb Symp Quant Biol 1994;59:181-6.
52. Kuriyama M, Harada N, Kuroda S, et al. Identification of AF-6 and canoe as putative targets for Ras. J Biol Chem 1996;27:607-10.
53. Han L, Colicelli J. A human protein selected for interference with Ras function interacts directly with Ras and competes with Raf1. Mol Cell Biol 1995;15:1318-23.
54. Matsumoto T, Yokote K, Tamura K, et al. Platelet-derived growth factor activates p38 mitogen-activated protein kinase through a Ras-dependent pathway that is important for actin reorganization and cell migration. J Biol Chem 1999;274:13954-60.
55. Rodriguez-Viciana P, Warne P, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994;370:527-32.
56. Perugini R, McDade T, Vittimberga F, Callery M. Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 2000;90:39-40.
57. Serrano M, Lin A, McCurrach M, Beach D, Lowe S. Oncogenic Ras provokes premature cell senescence associated with accumulation of p53 and p161NK4a. Cell 1997;88:593-602.
58. Sewing B, Wiseman A, Lloyd H, Land. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 1997;17:5588-97.
59. Olson M, Paterson H. Marshall C. Signals from Ras and Rho GTPases interact to regulate expression of p21 Waf1/Cip1. Nature 1998;394:295-9.
60. Kauffmann-Zeh A, Rodrigues-Viciana P, Ulrich E, et al. Suppression of c-Myc-induced apoptosis by ras signaling through PI(3)K and PKB. Nature 1997;385:544.